Publication | Closed Access

RIPK1 inhibitor ameliorates the MPP+/MPTP-induced Parkinson’s disease through the ASK1/JNK signalling pathway

Neurodegenerative DiseasesSignal TransductionSignaling PathwayMedicineCell DeathNeuropharmacologyDegenerative PathologyNeuroprotectionMpp+/mptp-induced Parkinson ’Ripk1 InhibitorPharmacologyCell BiologyCell SignalingMolecular Signaling